ArticleAntimicrobial agents and chemotherapy2025
Pathogen genomics in healthcare: overcoming barriers to proactive surveillance.
Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- A comprehensive AMR genotype-phenotype database (CABBAGE).Nucleic acids research · 2026Article
- Near-real-time whole-genome sequencing in hospital infection control: a narrative review.Infection · 2026Review
- Pathogen to read: a rapid, automated workflow for public health-ready microbial sequencing.BMC genomics · 2026Article
- Carbapenemases: epidemiology, detection and management in a changing global landscape.JAC-antimicrobial resistance · 2026Review
- From Bench to Insight: Rapid Pathogen Genomic Surveillance Workflow for SARS-CoV-2 and Emerging Pathogens.Genes · 2026Article
- Review
- Towards accurate genomic detection of fungal antimicrobial resistance: progress in fungal resistance databases and bioinformatic tools.Microbial genomics · 2026Review
- Genome sequencing for prevention of health-care-associated bacterial infections.Nature reviews. Microbiology · 2026Review
- Identifying intra-hospital Norovirus GII transmission using whole-genome sequencing.Genome medicine · 2026Article
- Integrated Phenotypic, Proteomic (MALDI-TOF MS), and Genomic (WGS) Investigation of a Prolonged Hospital Outbreak ofAntibiotics (Basel, Switzerland) · 2026Article
- Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Implementation and outcomes of a rapid response genomic hospital epidemiology programme at an academic medical centre over 7 years.The Lancet. Microbe · 2026Review
- Artificial intelligence enhances genomic surveillance in healthcare outbreak investigations.Infection control and hospital epidemiology · 2026Article
- The Role of Genomics in Advancing and Standardising Bacteriophage Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Applications of Genome Sequencing in Infectious Diseases: From Pathogen Identification to Precision Medicine.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Phenotype-First Diagnostic Framework for Tracking Fluoroquinolone Resistance inDiagnostics (Basel, Switzerland) · 2025Article
- Genomic sequencing surveillance of patients colonized with vancomycin-resistant enterococci improves detection of healthcare-associated transmission.BMC global and public health · 2025Article
- Uniting disciplines against antimicrobial resistance (AMR): highlights from a multidisciplinary inaugural AMR summit.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Review
- Strengthening Outbreak Detection in Africa to Achieve the 7-1-7 Global Framework: Challenges and Opportunities.Public health reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Pathogen genomic surveillance in healthcare has the potential to enhance patient safety by detecting outbreaks earlier, thereby reducing morbidity and mortality. Despite benefits, there are barriers to adoption, including cost, expertise, and lack of standardized methodologies and incentives. This commentary advocates for 1) investment from healthcare payors, public health, and regulatory bodies and 2) additional research on genomic surveillance for improving patient outcomes and reducing infections. Effective implementation will require strategic investment and cross-sector collaboration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.